2. Search Result
Search Result
Results for "

ATCC 43300

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161988
    Antimicrobial agent-34

    		Bacterial Infection Inflammation/Immunology
    Antimicrobial agent-34 (compound 4h) is an antibacterial agent (MIC = 1–4 μg/mL), with a clogP value of 9.14. Antimicrobial agent-34 has good plasma stability (HC50 of 131.1 μg/mL) and good membrane selectivity (HC50/MIC is 65.6), with rapid sterilization capability. Antimicrobial agent-34 destroys the integrity of bacterial cell membranes, induces an increase in intracellular reactive oxygen species, and leaks protein and DNA, ultimately leading to bacterial death. Antimicrobial agent-34 demonstrates significant in vivo antibacterial potency in a mouse sepsis model infected with Staphylococcus aureus ATCC43300 .
    Antimicrobial agent-34
  • HY-115965
    VP-4604

    		Bacterial Antibiotic Infection
    VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4604 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 4-8 µg/mL. VP-4604 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95% .
    VP-4604
  • HY-156122
    DHFR-IN-8

    		Dihydrofolate reductase (DHFR) Bacterial Infection
    DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=15.6 ng/mL) in mouse models of systemic infection and thigh infection .
    DHFR-IN-8
  • HY-115964
    VP-4556

    		Bacterial Antibiotic Infection
    VP-4556 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4556 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 8 µg/mL. VP-4556 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95% .
    VP-4556
  • HY-115965R
    VP-4604 (Standard)

    		Reference Standards Bacterial Antibiotic Infection
    VP-4604 (Standard) is the analytical standard of VP-4604. This product is intended for research and analytical applications. VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4604 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 4-8 μg/mL. VP-4604 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95%[1].
    VP-4604 (Standard)
  • HY-115407
    Cochliodone A

    		Bacterial Infection Cancer
    Cochliodone A is an active compound extracted from cultures of the deep-sea derived fungus Chaetomium sp. and has antibacterial and anticancer activity. Cochliodone A is toxic to a variety of bacteria, with MICs of 15.3 μg/mL (V. vulnificus), 32.7 μg/mL (V. rotiferianus), 15.9 μg/mL (S. aureus ATCC 43300), and 16.3 μg/mL (S . aureus CGMCC 1.12409). Cochliodone A also inhibits a variety of cancer cell lines, with IC50s of 28.1 μM (A549), 20.7 μM (HeLa), and 23.2 μM (Hep G2) .
    Cochliodone A
  • HY-156123
    DHFR-IN-9

    		Dihydrofolate reductase (DHFR) Bacterial Infection Cancer
    DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days) .
    DHFR-IN-9
  • HY-185443
    UCP1172

    		Bacterial Dihydrofolate reductase (DHFR) Infection
    UCP1172 is an antibacterial (Antibacterial) agent and Dihydrofolate reductase inhibitor, with an IC50 of 0.0089 μM against Staphylococcus aureus DfrB, 0.22 μM against DfrG, 0.41 μM against DfrA, and 0.030 μM against DfrK. UCP1172 potently inhibits the growth of MRSA/MSSA isolates carrying dfrG and dfrK (MIC values of 0.3125-0.625 μg/mL), shows weak activity against MRSA carrying dfrA (MIC of 5 μg/mL), and exerts extremely potent inhibitory effects on wild-type S. aureus ATCC 43300 (MIC of 0.0098 μg/mL). UCP1172 can be used in studies related to tuberculosis and Staphylococcus aureus infections .
    UCP1172

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: